Summary of findings for the main comparison. Intravesical bacterial interference versus placebo for preventing urinary tract infection in people with neuropathic bladder.
| Intravesical bacterial interference versus placebo for preventing urinary tract infection in people with neuropathic bladder | |||||
| Patient or population: people with neuropathic bladder Setting: outpatient Intervention: intravesical bacterial interference Comparison: placebo | |||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | |
| Risk with placebo | Risk with intravesical bacterial interference | ||||
| Symptomatic UTI Follow‐up: mean 12 months | 613 per 1,000 | 196 per 1,000 (49 to 729) | RR 0.32 (0.08 to 1.19) | 110 (3) | ⊕⊝⊝⊝1 VERY LOW |
| GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | |||||
1Risk of bias was assessed at high in most domains, with heterogeneity and small studies, suggesting that results overestimate intravesical bacterial interference versus placebo